F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With WegovyZepbound, which is already sold by Eli Lilly as the diabetes treatment Mounjaro, was shown to reduce patients' weight by as much as one-fifth in drug trials.
Source: F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovy (https://www.nytimes.com/2023/11/08/health/fda-tirzepatide-obesity-zepbound-wegovy.html)